IDEATE IPILIMUMAB DRUG EVALUATION IMMUNOTHERAPY IN SQUAMOUS NSCLC

USPTO USPTO 2012 CANCELLED - SECTION 8

Protect this trademark from copycats!

With our trademark monitoring alerts, you are automatically notified by email about copycats and free riders.

The US trademark IDEATE IPILIMUMAB DRUG EVALUATION IMMUNOTHERAPY IN SQUAMOUS NSCLC was filed as Word and figurative mark on 04/12/2012 at the U.S. Patent and Trademark Office.
It was registered as a trademark on 02/18/2014. The current status of the mark is "CANCELLED - SECTION 8".

Logodesign (Wiener Klassifikation)

#USPTO: 03.23.15 - Sperm cells, Micro-organisms, Amoebas #USPTO: 26.01.29 - Helixes, DNA helix #Set of lines evoking speed or propulsion #Other lines or bands #USPTO: 26.11.26 - Oblongs as carriers for words, letters or designs

Trademark Details Last update: December 4, 2021

Trademark form Word and figurative mark
File reference 4485747
Register number 85595704
Application date April 12, 2012
Entry date February 18, 2014
Expiration date February 18, 2024

Trademark owner

430 E. 29th Street, 14th Floor
10016 New York
US

Trademark representatives

P.o. Box 4000 08648-4000 Princeton US

goods and services

42 Scientific and computer services

ID: 13